|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1B
|
|
pubmed:dateCreated |
2005-4-8
|
|
pubmed:abstractText |
Gefitinib is an oral agent that inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR), which had antitumor activity in patients with previously treated non-small cell lung cancer (NSCLC). We analyzed the efficacy, toxicity and overall survival time of gefitinib treatment in patients with NSCLC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:AsahinaHajimeH,
pubmed-author:Dosaka-AkitaHirotoshiH,
pubmed-author:HattoriTakeshiT,
pubmed-author:ImuraMikadoM,
pubmed-author:IshidaTakashiT,
pubmed-author:IsobeHiroshiH,
pubmed-author:KikuchiEikiE,
pubmed-author:KikuchiJunkoJ,
pubmed-author:KinoshitaIchiroI,
pubmed-author:KonishiJunJ,
pubmed-author:MunakataMitsuruM,
pubmed-author:NakadateMegumiM,
pubmed-author:NishikawaShyuS,
pubmed-author:NishimuraMasaharuM,
pubmed-author:OguraShigeakiS,
pubmed-author:SekineSatokoS,
pubmed-author:ShinagawaNaofumiN,
pubmed-author:TakashimaRiouR,
pubmed-author:YamazakiKoichiK,
pubmed-author:YokouchiHiroshiH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
435-41
|
|
pubmed:meshHeading |
pubmed-meshheading:15816608-Adenocarcinoma,
pubmed-meshheading:15816608-Adult,
pubmed-meshheading:15816608-Aged,
pubmed-meshheading:15816608-Aged, 80 and over,
pubmed-meshheading:15816608-Antineoplastic Agents,
pubmed-meshheading:15816608-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15816608-Female,
pubmed-meshheading:15816608-Humans,
pubmed-meshheading:15816608-Lung Neoplasms,
pubmed-meshheading:15816608-Male,
pubmed-meshheading:15816608-Middle Aged,
pubmed-meshheading:15816608-Multivariate Analysis,
pubmed-meshheading:15816608-Proportional Hazards Models,
pubmed-meshheading:15816608-Quinazolines,
pubmed-meshheading:15816608-Retrospective Studies,
pubmed-meshheading:15816608-Sex Factors,
pubmed-meshheading:15816608-Smoking,
pubmed-meshheading:15816608-Time Factors,
pubmed-meshheading:15816608-Treatment Outcome
|
|
pubmed:articleTitle |
Analysis of the response and toxicity to gefitinib of non-small cell lung cancer.
|
|
pubmed:affiliation |
First Department of Medicine, Hokkaido University School of Medicine, Kita-ku, Sapporo 060-8638, Japan.
|
|
pubmed:publicationType |
Journal Article
|
